Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy.

Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy.

A method of monitoring Plasmodium falciparum viability ex vivo was used to compare the ability of different antimalarial drugs to arrest the progression of young parasites to mature, potentially damaging stages. Neither pyrimethamine-sulfadoxine nor quinine, the treatment of choice for severe, life-...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Watkins, WM, Woodrow, C, Marsh, K
Format:	Journal article
Język:	English
Wydane:	1993

Podobne zapisy

Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine.
od: Murphy, S, i wsp.
Wydane: (1995)

Pharmacology of absorption and distribution: optimal use of antimalarial drugs in the treatment of severe falciparum malaria in Kenya.
od: Watkins, WM, i wsp.
Wydane: (1994)

Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity.
od: Russell, B, i wsp.
Wydane: (2013)

Is malaria parasite ex-vivo viability reduction really “superior” to observed parasite clearance rate?
od: White, NJ, i wsp.
Wydane: (2020)

The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria.
od: Chotivanich, K, i wsp.
Wydane: (2000)

Serine Proteases of Malaria Parasite Plasmodium falciparum: Potential as Antimalarial Drug Targets
od: Asrar Alam
Wydane: (2014-01-01)

Questioning the claimed superiority of malaria parasite ex vivo viability reduction over observed parasite clearance rate?
od: White, NJ, i wsp.
Wydane: (2020)

Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand.
od: Wilairatana, P, i wsp.
Wydane: (1997)

The antimalarial activity of tafenoquine in falciparum malaria
od: White, NJ
Wydane: (2023)

Putative molecular markers of Plasmodium falciparum resistance to antimalarial drugs in malaria parasites from Ghana
od: Sena Adzoa Matrevi, i wsp.
Wydane: (2024-02-01)

Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.
od: Newton, P, i wsp.
Wydane: (2000)

Antimalarial activity of KAF156 in falciparum and vivax malaria
od: Nosten, F, i wsp.
Wydane: (2016)

PARASITIZED ERYTHROCYTE BINDING TO THROMBOSPONDIN IN FALCIPARUM-MALARIA
od: Sherwood, J, i wsp.
Wydane: (1986)

System biology approach for functional annotation of the genome of human malaria parasite plasmodium falciparum and antimalarial drug discovery
od: Naw, Wah Wah
Wydane: (2015)

Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs.
od: Supanaranond, W, i wsp.
Wydane: (1993)

Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.
od: Borrmann, S, i wsp.
Wydane: (2008)

Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria
od: Borrmann, S, i wsp.
Wydane: (2008)

Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.
od: Steffen Borrmann, i wsp.
Wydane: (2008-11-01)

Thrombospondin binding by parasitized erythrocyte isolates in falciparum malaria.
od: Sherwood, J, i wsp.
Wydane: (1987)

The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of <i>Plasmodium falciparum</i> Viability after Antimalarial Treatment In Vitro
od: Annabelle Walz, i wsp.
Wydane: (2023-01-01)

Artemisinin resistance and stage dependency of parasite clearance in Falciparum malaria
od: Intharabut, B, i wsp.
Wydane: (2019)

Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria.
od: Newton, P, i wsp.
Wydane: (2002)

Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers.
od: Lim, P, i wsp.
Wydane: (2013)

Investigating protein kinases in the malaria parasite as antimalarial drug targets
od: J. Bonilla, i wsp.
Wydane: (2020-12-01)

Measuring Hidden Parasites in Falciparum Malaria.
Wydane: (2005-08-01)

In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria.
od: Angus, B, i wsp.
Wydane: (1997)

Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria.
od: Stepniewska, K, i wsp.
Wydane: (2006)

Optimising statistical methodologies for estimating antimalarial efficacy for uncomplicated Plasmodium falciparum malaria
od: Dahal, P
Wydane: (2018)

A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.
od: Suputtamongkol, Y, i wsp.
Wydane: (2001)

Antimalarial activity of Malaria Box Compounds against Plasmodium falciparum clinical isolates
od: Jersley D. Chirawurah, i wsp.
Wydane: (2017-12-01)

Epidemic of Plasmodium falciparum Malaria Involving Substandard Antimalarial Drugs, Pakistan, 2003
od: Toby Leslie, i wsp.
Wydane: (2009-11-01)

Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children
od: Kamya Moses R, i wsp.
Wydane: (2008-06-01)

Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria
od: Stepniewska Kasia, i wsp.
Wydane: (2006-12-01)

A model for estimating total parasite load in falciparum malaria patients.
od: Gravenor, M, i wsp.
Wydane: (2002)

The Rare, the Best: Spread of Antimalarial-Resistant Plasmodium falciparum Parasites by Anopheles Mosquito Vectors
od: Antoine Berry, i wsp.
Wydane: (2021-10-01)

Plasma Concentration of Parasite DNA as a Measure of Disease Severity in Falciparum Malaria.
od: Imwong, M, i wsp.
Wydane: (2014)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
od: Phyo, A, i wsp.
Wydane: (2016)

Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.
od: Amukoye, E, i wsp.
Wydane: (1997)

Malaria in East Africa
od: Watkins, WM, i wsp.
Wydane: (1997)

Parasite multiplication potential and the severity of Falciparum malaria.
od: Chotivanich, K, i wsp.
Wydane: (2000)